All News
SLE Preview: abolishing refractory with CAR-T and better B-cell therapies
Inhibition of B cell activating factor (BAFF) and B cell depletion are the two most evaluated strategies over the last 15 years in the field of SLE therapeutics, with licensing of belimumab and off-label use of rituximab.
Read Article
ACR’s Run at Goliath (PCPs) (5.31.2024)
Dr. Jack Cush reviews the journal reports and articles from this past week on RheumNow.com. The ACR (and Cush) address their new website designed to educate PCPs and APPs - what do you think?
Read Article
The Window of Opportunity (5.24.2024)
Dr. Jack Cush reviews the journal reports and news from the past week on RheumNow.com. This week: blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis?
Read Article
Lupus Research Alliance Grants for Lupus Innovation
EurekAlert!
The Lupus Research Alliance (LRA) is proud to announce that nine international researchers are the recipients of this year’s Lupus Innovation Award (LIA).
Read Article
Precision medicine in Lupus is far from reality today. @Lupusreference @RheumNow #EULAR2024
Bella Mehta bella_mehta ( View Tweet)
Whats new in Lupus #EULAR2024 @Lupusreference lecture - many pearls.
Corticosteroids IV may be the way to go - referencing @AliDuarteMD team (better outcomes compared to oral steroids)
@RheumNow https://t.co/Fz1dZUVomF
Links:
Bella Mehta bella_mehta ( View Tweet)
Should we treat to target (T2T) for #SLE or just do SOC and gestalt (as most do in clinical practice)? @Lupusreference #EULAR24 @RheumNow
TheDaoIndex KDAO2011 ( View Tweet)
Dr. G Schett reported using CAR-T cell Rx in patients w/ 1. pedi-SLE 2. CNS lupus 3. refractory cases with success. Post- Rx vaccine response is fine, infection risk is less since pts no longer need steroids. He is still following the pts for relapse and AEs @RheumNow #EULAR24
TheDaoIndex KDAO2011 ( View Tweet)
Pt with LN, endocarditis, pericarditis, arthritis, rash failed CTX, MMF, BEL, and SOC. She is 1000 days post CAR-T cell. Off immunomodulating drugs. #SLE in remission clinically and serologically. - Dr G Schett #EULAR24 @RheumNow https://t.co/3vdMtO6VWI
TheDaoIndex KDAO2011 ( View Tweet)
🌎 Global disparities in steroid prescribing in #SLE
💊 HCQ assoc with decreased steroid use
📈 Other contributing factors may be prevalence, severity & phenotype of disease, plus access to DMARDs & biologics
📍SLE poster tour 15:30 TODAY
#EULAR2024
Abs #POS0013
@RheumNow https://t.co/7pL8kpeqOs
Mrinalini Dey DrMiniDey ( View Tweet)
#AB1039 Spanish study 76 LN patients postrenal transplant: 77% females, HTN (68%), LN class IV (42%), mean age 55. Graft loss in 35.5% b/c of acute rjx (22%), chronic rjx (22%), acute w/chronic rjx (22%), graft thrombosis 14.8%, recur LN (11%) #EULAR24 @rheumnow https://t.co/d82i0Z7LUB
TheDaoIndex KDAO2011 ( View Tweet)
Prospect study 174 SLE HCQ-Rx pts w/ whole-blood HCQ levels during pregnancy. 30 w/ flares(17%; 2.3% severe) & 28(16%) adverse preg outcomes. HCQ levels didnt predict APOs. BUT low (≤500) or no (≤200 ) HCQ levels assoc w/ severe maternal flares (9-13%) https://t.co/CHdd9Tuamk https://t.co/fFTr5MpiCx
Dr. John Cush RheumNow ( View Tweet)
Save the date! We are covering #EULAR24! We'll be sharing recaps, videos, and more. https://t.co/NMWtHB94Pi https://t.co/ok43pnagFg
Links:
Dr. John Cush RheumNow ( View Tweet)
Lupus Research Alliance Grants for Lupus Innovation
The LRA) is proud to announce that nine international researchers are the recipients of this year’s Lupus Innovation Award (LIA).
https://t.co/nAlpFyiyUO https://t.co/Rj2JzmmhHO https://t.co/8IG9EkyMad
Dr. John Cush RheumNow ( View Tweet)
Kaiser/California EHR study of #SLE pregnancies (2011-2020) - 657 pregnancies in 453 prs; The live birth rate = 74%, 23% w/ Spontaneous Ab, 2% ectopic/molar & <1% stillbirths. Variable outcomes by race & ethnicity, aPL status & nephritis history https://t.co/gvmYpTuFon https://t.co/9TeG8kfLmK
Dr. John Cush RheumNow ( View Tweet)
Do you have a rheumatology question or case for Dr. Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/qvVEUoNYi5 https://t.co/duw6jg5xpp
Dr. John Cush RheumNow ( View Tweet)
Upside/Downside of Steroids in Lupus Nephritis
A systematic review of randomized clinical trials of patients with biopsy-proven lupus nephritis (LN) demonstrates both the benefits and harms to early glucocorticoid (GC) regimens on lupus outcomes.
https://t.co/T88365IT9r https://t.co/xe5AmErLy2
Dr. John Cush RheumNow ( View Tweet)
Full read review of the benefits & impact of hydroxychloroquine in #SLE. Benefits on:
- T cells, cytokines, TLR signaling
- VTE prevention
- Decr CV risks
- Glucose & lipid benefits
- Pregnancy
https://t.co/bio9cYCIeb https://t.co/zfyUBaecbu
Dr. John Cush RheumNow ( View Tweet)
Small-molecule Drugs to Treat Systemic Lupus Erythematosus
A metanalysis of randomized controlled trials (RCTs) on treatments of systemic lupus erythematosus (SLE), confirm the efficacy of several targeted small-molecule drugs.
https://t.co/LKLUT8kLSk https://t.co/1SbUbiCpYs
Dr. John Cush RheumNow ( View Tweet)
SLE Cost of Care and Disease Activity
A longitudinal, multinational study shows that SLE patients achieving remission or low disease activity incur lower overall direct/indirect (DCs, ICs) healthcare costs than those with persistent activity.
https://t.co/Rk7SNpHaKu https://t.co/yvJ4qw1YCJ
Dr. John Cush RheumNow ( View Tweet)
